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Tissue factor pathway inhibitor (TFPI) is a Kunitz-type inhibitor that regulates the initiation of tissue factor-mediated coagulation.
Recent reports in the literature have described variable results using different methodologies for TFPI measurement. In this study,
we used one clotting and two amidolytic methodologies to assess TFPI functional levels. The study groups included normal healthy
donors as well as patients with acute hepatitis, diabetes, coronary artery bypass graft operations, deep vein thrombosis, and prior to
and during heparin therapy. The aims were to compare the results obtained in normal plasma using different assay systems, to
compare TFPI levels in a range of clinical samples, including those previously not determined using a clotting methodology, and to
report TFPI levels in patient groups previously not investigated. The results clearly demonstrate poor correlation between
functional TFPI values using the different methodologies, highlighting the requirement for standardization. Blood Coagul
Fibrinolysis 11:327±333 # 2000 Lippincott Williams & Wilkins.
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Introduction
There are reports in the literature of poor correla-
tion between results obtained using different
methodologies for tissue factor pathway inhibitor
(TFPI) measurement. These have included discre-
pancies between functional and antigenic method-
ologies [1±3], as well as variable results using the
clotting and amidolytic methodologies [4±6]. How-
ever, there are no reports that have used functional
methods to directly compare levels of TFPI in
normal plasma and clinical samples.
It was therefore the aim of this study to evaluate
different functional methodologies for TFPI meas-
urement to determine TFPI levels in both normal
plasma and in plasma samples from clinical groups.
Two amidolytic assays and a clotting endpoint
methodology were established. The clinical groups
included patients with acute hepatitis, diabetics,
patients who had undergone coronary artery bypass
graft operations (postCABG), patients with deep
vein thrombosis (DVT), and a group of patients
prior to and during heparin therapy.
Materials and methods
Puri®ed factor VII (FVII) and factor X (FX) were
purchased from Sigma Chemical Company (St. Louis,
Missouri, USA). The recombinant tissue factor (TF)
Innovin1 was obtained from Baxter Diagnostics
(Deer®eld, Illinois, USA). Prothrombinex1 was sup-
plied courtesy of the Australian Red Cross (WA
Branch) Blood Transfusion Service (Perth, WA,
Australia). Normal serum albumin was purchased
from the Commonwealth Serum Laboratories (Mel-
bourne, Victoria, Australia). A selected synthetic
peptide substrate (S-2222) was purchased from Chro-
mogenix (Molndal, Sweden). Microtitre trays speci®c
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for glycoproteins were obtained from Nunc (Max-
isorp, number 442404; Melbourne, Victoria, Austra-
lia). The glucose hectokinase kit for the determination
of glucose was purchased from Boehringer Mannheim
Systems (Castle Hill, NSW, Australia).
Collection of samples
Citrated plasma was obtained by drawing nine parts
whole blood into one part 0.109 mol/l sodium
citrate, and centrifuging at 1200 3 g at 48C for
10 min. Plasma was collected and then centrifuged
again at 3000 3 g at 48C for 20 min. Reference
plasma was pooled from 20 healthy donors and
designated as containing 1 U/ml TFPI in the test
systems used. All normal and clinical plasmas were
stored at ÿ708C prior to testing.
Patients included into the acute hepatitis group
were not receiving anticoagulant therapy. Samples
from postCABG patients were less than 48 h post-
operation and were receiving therapeutic doses of
unfractionated heparin. Patients with DVT were
undergoing a therapeutic regime of unfractionated
heparin. Diabetic patients were characterized by
markedly elevated serum glucose and were not
receiving anticoagulant therapy. Plasma was also
obtained from patients with miscellaneous clinical
problems during heparin anticoagulant therapy. Pa-
tients with DVT were excluded from this group.
Preparation of human brain thromboplastin
Human brain tissue factor was prepared essentially
by the method of Hjort [7].
Coagulation screening tests
International Normalised Ratio (INR) and activated
partial thromboplastin time (aPTT) screening were
performed using an automated coagulation analyser
(Electra1 MLA-1000) to determine clotting times.
Tests were performed in duplicate.
Amidolytic assays
A `¯uid assay' and a `binding assay' were performed
as described previously [8]. For the ¯uid assay, a
reaction mixture was initially prepared using equal
volumes of TF (neat), FVII (0.033 U/ml), FX
(0.025 U/ml) and calcium chloride (0.025 mol/l),
incubated at room temperature for 30 min, then
stored at ÿ708C until required. To the wells of
microtitre trays, 50 ìl plasma and 50 ìl aliquots of
reaction mixture were added. After incubation for
10 min at 378C, 50 ìl FX (0.4 U/ml) and S-2222
(2.7 mmol/l) were added and incubated for 25 min at
378C. To terminate the reaction, 50 ìl of 50% acetic
acid was added and the absorbance read at 405 nm
on a Titertek1 Multiskan microtitre tray reader.
The binding assay was performed by initially
incubating 100 ìl TF (neat) overnight at 48C in the
wells of microtitre trays. After washing with Tris-
buffered saline (containing 0.01 mol/l Tris,
0.125 mol/l CaCl2, 0.15 mol/l NaCl, 0.05% sodium
azide and 0.1% normal serum albumin; pH 7.3),
50 ìl prothrombinex (containing 1 U/ml FX and
trace amounts of FVII) was incubated at 378C for
1 h. Following further washing, 50 ìl plasma was
added and incubated at 378C for 15 min. The
samples were again washed, followed by the addi-
tion of 50 ìl S-2222 (2.7 mmol/l). After 30 min
incubation at 378C, the reaction was stopped with
the addition of 50 ìl of 50% acetic acid, and the
absorbance read at 405 nm using the microtitre tray
reader.
TFPI coagulation inhibition time
The TFPI coagulation inhibition time (TCIT) reac-
tion mixture consisted of 50 ìl diluted human tissue
factor [1/4000 dilution in TBS buffer (0.05 mol/l
Tris, 0.15 mol/l NaCl; pH 7.2)], 50 ìl test plasma
and 50 ìl reference plasma. The test plasma was heat
precipitated at 568C for 15 min to remove ®brinogen
and other coagulation factor activity. The TCIT
reaction mixture was incubated at 378C for 3 min.
One hundred microlitres of 0.025 mol/l CaCl2 was
then added to initiate coagulation and the clotting
time recorded using the Coag-a-Mate1 XM Analy-
ser (Organon Teknika, Boxtel, The Netherlands).
Each TFPI assay was optimized for reagent
activity using normal plasma.
Glucose assessment in diabetic patients
Assessment of glucose levels in plasma from diabetic
patients was performed using the Hitachi Boehrin-
ger Mannheim 917 Automated Analyser. Glucose
levels were determined using a commercial glucose
hectokinase colourimetric/enzymatic method (Boeh-
ringer Mannheim Systems).
Statistical analysis
Paired Student's t tests were performed to compare
the means of sets of data. P , 0.05 was considered
statistically signi®cant.
Results
Normal and clinical samples were screened using an
INR and aPTT. Glucose levels were determined in
diabetic patients. A summary of the data is pre-
sented in Table 1.
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Normal and clinical samples were assessed for
functional TFPI using the ¯uid assay, binding assay
and TCIT. A summary of the data is presented in
Table 2. There were no statistically signi®cant
differences between the mean TFPI in normal
plasma obtained using the three TFPI methodologies
(P , 0.05). Across all three assays, there were
statistically signi®cant differences in the mean TFPI
between normal plasma and hepatitis patients
(P  0.0446), diabetics (P  0.0002), postCABG pa-
tients (P  0.0002), patients with DVT (P  0.0001),
preheparin plasma (P  0.026) and postheparin plas-
ma (P  0.0001). There were statistically signi®cant
differences between the mean TFPI in diabetic
patients using the ¯uid and binding assays
(P  0.0008), and the binding assay and TCIT
(P  0.0342). There were statistically signi®cant
differences between the mean TFPI in DVT patients
using the binding assay and TCIT (P  0.0342).
There were statistically signi®cant differences be-
tween the mean TFPI in postheparin plasma using
the ¯uid and binding assays (P  0.0005), ¯uid assay
and TCIT (P  0.0213), and the binding assay and
TCIT (P  0.0034). There were statistically signi®-
cant differences between the mean TFPI in pre- and
post-heparin using the ¯uid and binding assays
(P  0.0001), ¯uid assay and TCIT (P  0.001), and
the binding assay and TCIT (P  0.041). There were
no other statistically signi®cant differences between
the mean TFPI in patient groups using the three
TFPI methodologies (P . 0.05) (Table 2).
Table 3 summarizes the correlation coef®cients
for data obtained using the three functional TFPI
assays in assessing the groups of normal and clinical
samples. The average correlation across all samples
was 0.44 using the ¯uid assay and binding assay,
0.48 between the ¯uid assay and TCIT, and 0.35
between the binding assay and TCIT. There were
statistically signi®cant differences between the re-
sults for all normal and clinical samples using the
¯uid and binding assays (P  0.0001), and binding
assay and TCIT (P  0.0001). There was no statisti-
cally signi®cant difference between the mean TFPI
in all normal and clinical samples using the ¯uid
assay and TCIT (P  0.1946).
Discussion
There was no signi®cant difference between the
mean TFPI in normal plasma obtained using each








Normal 20 23.0 1.10 30.1
Hepatitis 6 48.8 1.07 28.8
Diabetes 24 58.8 1.23 32.9 15.9
PostCABG 18 70.1 1.38 44.2
DVT 18 48.8 1.90 63.4
Preheparin 16 62.2 1.24 32.4
Postheparin 16 62.2 1.28 70.2
INR, International Normalised Ratio; aPTT, activated partial thromboplastin time; CABG,
coronary artery bypass graft; DVT, deep vein thrombosis.
Table 2. Summary of tissue factor pathway inhibitor (TFPI) data in normal and clinical samples using the ¯uid assay, binding assay and
TFPI coagulation inhibition time (TCIT)
Fluid assay Binding assay TCIT
Sample Mean SD Range Mean SD Range Mean SD Range
Normal 1.11 0.36 0.52±1.86 1.11 0.29 0.53±1.57 1.12 0.34 0.57±1.66
Hepatitis 0.94 0.46 0.54±1.65 0.84 0.21 0.62±1.07 0.87 0.13 0.72±1.04
Diabetes 1.00 0.33 0.57±1.72 0.83 0.21 0.53±1.54 0.99 0.34 0.51±1.84
PostCABG 0.91 0.33 0.46±1.40 0.80 0.15 0.51±1.09 0.88 0.36 0.52±1.91
DVT 0.78 0.26 0.35±1.40 0.74 0.15 0.48±0.95 0.90 0.34 0.31±1.40
Preheparin 1.05 0.39 0.50±1.95 0.82 0.17 0.54±1.15 1.06 0.39 0.55±1.69
Postheparin 2.35 1.09 1.05±4.70 1.14 0.13 0.78±1.34 1.68 0.67 0.89±3.20
Mean, standard deviation (SD) and range of TFPI values are expressed in U/ml.
CABG, coronary artery bypass graft; DVT, deep vein thrombosis.
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assay system. The mean TFPI obtained using the
¯uid (1.11 U/ml) and binding (1.11 U/ml) assays in
the assessment of 20 normal plasma samples was
higher than other reports in the literature [9±13].
The higher TFPI reported in this study may be due
to the number of samples used and individual
plasma variation. There are no detailed reports in
the literature that describe functional levels of TFPI
in normal plasma using a clotting methodology. The
normal TFPI range taken across the three TFPI
assays was 0.52±1.86 U/ml. This range of functional
TFPI values is similar to other studies [8±14].
The mean TFPI in six patients with acute hepatitis
was lower in comparison with normal plasma. There
are no previous reports of functional TFPI levels in
patients with acute hepatitis, although normal levels
have been reported in patients with other liver
disorders. These include hepatocellular disease
[9,15], acute and chronic liver disease [9,16] and
decompensated cirrhosis [17]. Increased levels of
functional TFPI have previously been reported in
patients with chronic liver disease [13]. The degrada-
tion and clearance of TFPI is controlled to a signi®-
cant extent by the liver [18]. There is no evidence
from the study presented here that altered function
of the liver, due to acute hepatitis, contributed
toward increased functional levels of TFPI in the
plasma of these patients. Indeed, the lower TFPI
values reported here could possibly be due to
increased clearance, utilization or consumption of
the inhibitor associated with in¯ammatory pro-
cesses.
The mean level of functional TFPI in diabetic
patients reported in this study was similar to a
previous report [13]. The results in the 24 diabetic
patients in this study were within the usually
accepted normal range. Interestingly, the mean level
for TFPI in diabetic plasma was signi®cantly re-
duced in comparison with the mean level in normal
plasma samples. The signi®cant reduction in func-
tional TFPI in the diabetic group is largely due to
values obtained using the binding assay, which may
re¯ect different forms of TFPI or other unknown
in¯uences.
Diabetics, particularly those in which the disease
is severe, frequently present with thrombotic pro-
blems as well as hypercholesterolaemia. The group
of patients in this study had a marked increase in
mean glucose concentration, demonstrating poor
control of glucose levels, and normal plasma TFPI
levels as measured in the ¯uid assay and TCIT.
However, the low result for the binding assay
suggests altered TFPI functional availability. It is
possible altered lipoprotein pro®les interfere with
TFPI function as assayed in the binding method-
ology. Studies are continuing to elucidate this
phenomenon.
Patients who underwent CABG operations
demonstrated a signi®cant reduction in the mean
level of functional TFPI after surgery when com-
pared with normal patients. It has previously been
reported that TFPI levels are reduced during and
after operative procedures [19]. All patients in this
study received unfractionated heparin postopera-
tively. An increase in TFPI in the postCABG
patients was therefore expected. The slight decrease
in functional TFPI using all three assays in these
patients does not correlate to expected results.
Decreased levels of TFPI during surgery may
indicate signi®cant consumption of the inhibitor or
may re¯ect a physiological response to under-
regulate TF-mediated coagulation.
Table 3. Summary of correlation coef®cients obtained from data using ¯uid assay, binding









Normal 0.18 0.26 0.08
Hepatitis 0.41 0.81 0.14
Diabetes 0.62 0.40 0.25
PostCABG 0.48 0.23 0.10
DVT 0.33 0.09 0.20
Preheparin 0.54 0.29 0.20
Postheparin 0.03 0.38 0.44
Average correlation 0.44 0.48 0.35
P value 0.0001 0.1946 0.0001
With the exception of the P values, results are expressed as a correlation coef®cient. P , 0.05
considered statistically signi®cant. CABG, coronary artery bypass graft; DVT, deep vein
thrombosis.
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Signi®cantly decreased levels of functional TFPI
were demonstrated in this study in patients with
DVT in comparison with normal plasma. Functional
levels of TFPI in patients with DVT have been
reported to be within the normal range [15]. The
reduced levels were especially demonstrable using
the binding assay. The decreased TFPI levels
reported in this study may indicate consumption of
TFPI, a mild de®ciency of the inhibitor or reduced
availability of TFPI in patients within this group.
Decreased levels of TFPI may therefore contribute
toward the thrombotic tendencies seen in these
patients.
An average 1.8-fold increase in functional TFPI
was observed in 16 patients after heparin administra-
tion using all three assay systems. The postheparin
effect of TFPI was therefore demonstrated using
each assay system in this study. The level of
functional TFPI observed during heparin therapy in
the patients in this study was slightly lower than
peak levels in comparison with other reports [20±
22]. This is likely to be due to the small increase in
TFPI as measured in the binding assay. This ratio
was 1.39, compared with 2.24 using the ¯uid assay,
and 1.58 using the TCIT. These variations in results
may be due to the different forms of TFPI released
from the endothelium and whether these are de-
tected using the TFPI methodologies in this study.
There were statistically signi®cant differences be-
tween the mean TFPI in diabetics, patients with
DVT and postheparin treatment using different
assay methodologies. The functional TFPI in the
same plasma samples using different assay systems
clearly demonstrate poor correlation between re-
sults. There was poor correlation between all assays
when comparing individual samples. The highest
correlation across all samples was using the ¯uid
assay and the TCIT (r  0.48). The correlation
between results using the ¯uid assay and binding
assay (r  0.44), and the binding and TCIT
(r  0.35) also indicated that there was poor inter-
assay reproducibility. The results of this study
clearly demonstrate the poor inter-assay reproduci-
bility between functional TFPI assays. Similar ®nd-
ings have been reported in which large discrepancies
existed between TFPI results using a clotting assay
and a synthetic peptide substrate assay [4±6].
The poor correlation between the results obtained
using the three functional assays could have two
explanations. The functional activity of TFPI in an
individual plasma may be due to the different forms
of TFPI present in the sample. Alternatively, the
individual mechanisms of the functional TFPI assay
systems used in this study may detect only speci®c
forms of TFPI. The functional assays used in this
study were selected as they may more closely re¯ect
the in vivo processes of the inhibition of TF-
mediated coagulation. These assay systems deter-
mine functional TFPI based on the ability of the
inhibitor to bind to TF-FVIIa in the presence of
activated FX. In particular, the binding assay con-
sistently demonstrated lower results in comparison
with the other TFPI methodologies, in all patient
groups.
The three functional TFPI assays used in this
clinical study may detect different forms of the
inhibitor. In plasma, TFPI is present as a full-length
molecule, as well as truncated, lipoprotein-asso-
ciated, lipoprotein-free and endothelial-associated
forms. The precise role that each of these forms of
TFPI has in the regulation of TF-mediated coagula-
tion is not clearly understood. The detection of each
of these different forms of TFPI using functional
methodologies has also not been characterized.
It is speculated that the different forms of TFPI
present in plasma, lipoprotein associated, truncated
and free, may be detected to varying degrees in
current functional TFPI methodologies. These forms
of TFPI may therefore contribute to the low
correlation in the same plasma samples using these
assays. Another explanation is that the different
form(s) of TFPI present in plasma may be depen-
dent on the clinical situation of the patient. It is well
documented that patients undergoing heparin ther-
apy have marked increases in functional TFPI due
to the release of the inhibitor from the endothelium.
It has been demonstrated in this study that func-
tional TFPI levels were increased using the three
TFPI assay systems. The degree of increase was
different as determined by the three methodologies
in this study, and this may be due to the varying
ability of the TFPI assays to detect endothelial-
released TFPI.
Another explanation for the poor correlation
between functional TFPI assays could be due to the
mechanisms within each assay. Although the syn-
thetic peptide substrate assays and TCIT each meas-
ured the functional activity of TFPI in a plasma
sample, the latter did not have long incubation
periods. This implied that the TCIT was more
dependent on the initial rate kinetics of the inhibi-
tion by TFPI, and therefore may not re¯ect the total
inhibitory capacity of TFPI in the sample [23]. This
may account for the poor correlation between
assays. Additionally, as TF-mediated coagulation
occurs within seconds in vivo, the anticoagulant
ability of TFPI re¯ected in the TCIT is more likely
to re¯ect in vivo conditions [21].
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The mechanisms of the binding assay may also
contribute to the poor reproducibility between TFPI
methodologies. This assay is dependent on the
binding of TF and phospholipids to a surface prior
to the addition of FVII, FX and a source of TFPI.
The consistently lower results that were demon-
strated using the binding assay, in comparison with
the ¯uid assay, may be due to the structural
arrangement of phospholipids with TF. The binding
of activated FVII and activated FX, and therefore
TFPI, may be affected, resulting in the detection of
lower amounts of TFPI in this assay system.
The ability of TFPI to inhibit clotting in vivo is
likely to be due to the free form of the inhibitor
present in plasma [24], or by TFPI associated with
platelets near the site of vessel injury. It is tempting
to suggest the measurement of the free form of TFPI
in a plasma sample would therefore be of most
signi®cance. The major problem in determining
functional levels of free TFPI is that this form of the
inhibitor is a minor component of total TFPI. The
sensitivity of current methodologies do not accu-
rately quantitate free TFPI. Future work must focus
on isolating the different forms of TFPI, investiga-
tion of the inhibitory role of the different forms of
the inhibitor and the determination of the particular
forms of TFPI that are measured in currently avail-
able functional TFPI methods. This will lead to
standardization of these assays.
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